SOPHiA DDM™ Enhanced Clinical Exome Solution

A comprehensive solution combining a capture-based enrichment kit and the SOPHiA DDM™ platform for advanced clinical exome analysis, featuring targeted enhancements to increase coverage in critical regions and detect complex variants in a single workflow.

Detailed Description

Operating Principle

A genomic application integrating a capture enrichment kit with the advanced analytical modules of the SOPHiA DDM™ platform. The solution expands the SOPHiA DDM™ Clinical Exome Solution v3 kit with targeted probes to boost coverage in critical genomic regions and dedicated algorithms that reliably detect hard-to-identify variants, all within a single test.

SOPHiA Clinical Exome Solution

Clinical Applications

Specially designed to advance the study of rare and hereditary diseases, and to consolidate indications such as carrier screening and hereditary cancer into a unified workflow.

Benefits

Increases laboratory efficiency by consolidating multiple tests into one. Achieves sensitivities comparable to targeted panels in critical genomic regions. Reduces the complexity of genomic data interpretation with specific features through the use of dedicated software.

Intended Audience/User

Laboratories seeking an expanded clinical exome solution for multiple indications (rare/hereditary diseases, carrier screening, hereditary cancer) with advanced analytical capabilities and comprehensive support.

Key Features

Expanded coverage of the clinical exome + mitochondrial genome + ~200 relevant non-coding variants.
Specific enhancements for hereditary cancer (94 genes) and carrier screening (155 genes).
Reliable detection of complex variants: 1–2 exon CNVs, Alu insertions, gene conversions (PMS2/PMS2CL, SMN1/SMN2, CYP21A2), Boland inversions (MSH2), repetitive tracts (CFTR).
Proven analytical performance: SNV/Indel sensitivity 99.8%; precision 99.0%; >99% of on-target regions at >25×/>50× coverage.
Unified and efficient workflow with advanced interpretation tools: ACMG scoring, virtual panel generation, duo and trio analysis, and reporting.
Direct integration capabilities with Alamut™ Visual Plus.
Access to the SOPHiA Genetics community to securely and anonymously share knowledge among specialists.
Expert support and cloud storage: secure, unlimited storage following industrial encryption standards and restricted access control to empower the interpretation of challenging variants.

Area:

Exomes, Hereditary and/or Rare Diseases, Molecular Genetics
Consult our experts

Google reCaptcha: Invalid site key.

Related products

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)

MSK-IMPACT® / MSK-IMPACT® FLEX

Decentralised, in-house comprehensive genomic profiling (CGP) solution for solid tumours, based on hybrid capture next-generation sequencing (NGS). Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it features a robust matched tumour-normal sequencing approach for filtering germline variants and clonal haematopoiesis. Detailed description Operating principle The decentralised MSK-IMPACT® powered with SOPHiA DDM™ solution enables…
SOPHIA Genetics
Next Generation Sequencing (NGS)

Homologous Recombination Solutions (HRS)

Portfolio of hybrid capture-based NGS solutions for the analysis of genes involved in homologous recombination repair (HRR) and the study of alterations associated with the homologous recombination pathway in different types of cancer. The range includes three scalable panels designed to meet different analytical needs: mini HRS, HRS and Extended HRS (ExtHRS). Detailed description Operating…
SOPHIA Genetics
Next Generation Sequencing (NGS)

Homologous Recombination Deficiency (HRD) Solution

Homologous Recombination Deficiency (HRD) Solution NGS- and low-pass whole-genome sequencing (low-pass WGS)-based solution for determining homologous recombination deficiency (HRD) status in ovarian cancer. Operating Principle This comprehensive solution, available as CE-IVD and for Research Use Only (RUO), is designed to support the determination of tumour HRD status in patients with ovarian cancer. It integrates two…
SOPHIA Genetics
Next Generation Sequencing (NGS)